ARTICLE | Company News
Ambrilia cancer, infectious news
October 6, 2008 7:00 AM UTC
Ambrilia restructured and reduced headcount by 14 (33%) to 29 and will look to divest its octreotide (C2L) and goserelin programs before year end. The company also put R&D for its preclinical antiviral program on hold. Octreotide is in Phase III testing to treat acromegaly. Goserelin is in Phase I/II testing to treat hormone-sensitive prostate cancer (HSPC). ...